Avidity Biosciences, Inc (RNA)

On Wednesday, 807 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Amazon.com ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $227.78 per unit.

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 24.47% and 19.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress.

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in KalVista Pharmaceuticals Inc (KALV), where a total of 2,404 contracts have traded so far, representing approximately 240,400 underlying shares. That amounts to about 126.1% of KALV's average daily trading volume over the past month of 190,710 shares..

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Michael MacLean, currently the chief financial officer, has expanded his role to include responsibilities as chief business officer.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting at the American Academy of Neurology 2022 Annual Meeting in Seattle, Washington, April 2-7, 2022.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Avidity Biosciences Inc (RNA), where a total of 6,182 contracts have traded so far, representing approximately 618,200 underlying shares. That amounts to about 243% of RNA's average daily trading volume over the past month of 254,355 shares..

Benzinga Pro data, Avidity Biosciences (NASDAQ:RNA) reported Q4 sales of $1.85 million. Earnings fell to a loss of $38.54 million, ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced they will be presenting an oral presentation and multiple poster presentations at the 2022 MDA Clinical & Scientific Conference in Nashville, Tennessee, March 13-16, 2022.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $295.07 per unit.

Avidity Biosciences (NASDAQ:RNA) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors ...

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -12.33% and 15.82%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent corporate progress.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its support for Rare Disease Day® and highlights the importance of raising awareness about rare diseases and their impact on people's lives.

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -1.73% and 33.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the appointment of Steve Hughes, M.D. as chief medical officer. Dr. Hughes has over 20 years of experience building and leading clinical development and medical affairs teams at prominent biopharmaceutical companies.

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Avidity management team will be participating at the following conferences:

It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do both...

Gainers Avidity Biosciences (NASDAQ:RNA) shares increased by 42.2% to $20.2 during Thursday's after-market session. The market value ...

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever ...

Gainers Cognition Therapeutics (NASDAQ:CGTX) shares rose 14.9% to $6.62 during Wednesday's after-market session. The market value of ...

Investment company Rtw Investments, Lp (Current Portfolio) buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, argenx SE, Macrogenics Inc, sells Quidel Corp, Protagonist Therapeutics Inc, MiMedx Group Inc, , Castle Biosciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Rtw Investments, Lp.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $212.07 per unit.

Keybanc boosted the price target on Broadcom Inc. (NASDAQ: AVGO) from $575 to $710. Broadcom shares fell 0.9% to close at $583.42 on ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it will be hosting a live webcast investor and analyst day event titled "Volume 3: Delivering on AOCs - FSHD" at 11:00am ET.

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -7.94% and 44.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?